Introduction to the Theme “New Insights, Strategies, and Therapeutics for Common Diseases”

Literature Cited

1. 1. 

   Pandamooz S, Jurek B, Meinung C-P, Baharvand Z, Sahebi Shahem-abadi A et al. 2022. Experimental models of SARS-CoV-2 infection: possible platforms to study COVID-19 pathogenesis and potential treatments. Annu. Rev. Pharmacol. Toxicol. 62:25–53
   [Google Scholar]
2. 2. 

   Sriram K, Insel PA. 2020. A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance. Br. J. Pharmacol 177:4825–44
   [Google Scholar]
3. 3. 

   Bohn MK, Hall A, Sepiashvili L, Jung B, Sheele S, Adeli K. 2020. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology 35:288–301
   [Google Scholar]
4. 4. 

   Sridhar S, Nicholls J. 2021. Pathophysiology of infection with SARS-CoV-2—what is known and what remains a mystery. Respirology 26:652–65
   [Google Scholar]
5. 5. 

   Mirzadeh Z, Faber CL, Schwartz MW. 2022. Central nervous system control of glucose homeostasis: a therapeutic target for type 2 diabetes?. Annu. Rev. Pharmacol. Toxicol. 62:55–84
   [Google Scholar]
6. 6. 

   Induri SNR, Kansara P, Thomas SC, Xu F, Saxena D, Li X. 2022. The gut microbiome, metformin, and aging. Annu. Rev. Pharmacol. Toxicol. 62:85–108
   [Google Scholar]
7. 7. 

   Glossmann HH, Lutz OMD. 2019. Metformin and aging: a review. Gerontology 65:581–90
   [Google Scholar]
8. 8. 

   Patel RB, Shah SJ. 2019. Drug targets for heart failure with preserved ejection fraction: a mechanistic approach and review of contemporary clinical trials. Annu. Rev. Pharmacol. Toxicol 59:41–63
   [Google Scholar]
9. 9. 

   Shah KS, Fang JC. 2022. Sodium-glucose cotransporter 2 inhibitors in heart failure. Annu. Rev. Pharmacol. Toxicol. 62:109–20
   [Google Scholar]
10. 10. 

    Vallon V, Verma S. 2021. Effect of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol 83:503–28
    [Google Scholar]
11. 11. 

    Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E et al. 2021. Empagliflozin in heart failure with a preserved ejection fraction. New Engl. J. Med 385:1451–61
    [Google Scholar]
12. 12. 

    Drazner MH. 2021. SGLT2 inhibition in heart failure with a preserved ejection fraction—a win against a formidable foe. New Engl. J. Med 385:1522–24
    [Google Scholar]
13. 13. 

    Bouabdallaoui N, Tardif J-C. 2022. Repurposing colchicine for heart disease. Annu. Rev. Pharmacol. Toxicol. 62:121–29
    [Google Scholar]
14. 14. 

    Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A et al. 2020. Colchicine in patients with chronic coronary disease. New Engl. J. Med 383:1838–47
    [Google Scholar]
15. 15. 

    Russell MD, Bukhari M, Shah AM, Galloway JB. 2021. Colchicine and the heart: old friends, old foes. Rheumatology 60:2035–36
    [Google Scholar]
16. 16. 

    Westaby D, Fenor de La Maza MdlD, Paschalis A, Jimenez-Vacas JM, Welti J et al. 2022. A new old target: androgen receptor signaling and advanced prostate cancer. Annu. Rev. Pharmacol. Toxicol. 62:131–53
    [Google Scholar]
17. 17. 

    Gudas LJ. 2022. Synthetic retinoids beyond cancer therapy. Annu. Rev. Pharmacol. Toxicol. 62:155–75
    [Google Scholar]
18. 18. 

    Gencheva R, Arnér ESJ. 2022. Thioredoxin reductase inhibition for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 62:177–96
    [Google Scholar]
19. 19. 

    Garcia-Cremades M, Solans BP, Strydom N, Vrijens B, Pillai GC et al. 2022. Emerging therapeutics, technologies, and drug development strategies to address patient nonadherence and improve tuberculosis treatment. Annu. Rev. Pharmacol. Toxicol. 62:197–210
    [Google Scholar]
20. 20. 

    Bartesaghi R, Vicari S, Mobley WC. 2022. Prenatal and postnatal pharmacotherapy in Down syndrome: the search to prevent or ameliorate neurodevelopmental and neurodegenerative disorders. Annu. Rev. Pharmacol. Toxicol. 62:211–33
    [Google Scholar]
21. 21. 

    Abd-Elrahman KS, Ferguson SSG. 2022. Noncanonical metabotropic glutamate receptor 5 signaling in Alzheimer's disease. Annu. Rev. Pharmacol. Toxicol. 62:235–54
    [Google Scholar]
22. 22. 

    Cuadrado A. 2022. Brain-protective mechanisms of transcription factor NRF2: toward a common strategy for neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 62:255–77
    [Google Scholar]
23. 23. 

    Torrente L, DeNicola GM. 2022. Targeting NRF2 and its downstream processes: opportunities and challenges. Annu. Rev. Pharmacol. Toxicol. 62:279–300
    [Google Scholar]
24. 24. 

    Gordon T, Karey E, Rebuli ME, Escobar YN, Jaspers I, Chen LC 2022. E-cigarette toxicology. Annu. Rev. Pharmacol. Toxicol. 62:301–22
    [Google Scholar]
25. 25. 

    Benedetti F, Frisaldi E, Shaibani A 2022. Thirty years of neuroscientific investigation of placebo and nocebo: the interesting, the good, and the bad. Annu. Rev. Pharmacol. Toxicol. 62:323–40
    [Google Scholar]
26. 26. 

    Page S, Khan T, Kühl P, Schwach G, Storch K, Chokshi H. 2022. Patient centricity driving formulation innovation: improvements in patient care facilitated by novel therapeutics and drug delivery technologies. Annu. Rev. Pharmacol. Toxicol 62:341–63
    [Google Scholar]